Such an approach would be of potential benefit to the subset of patients with ALK-driven neuroblastoma who either acquire mutations in the RAS-MAPK pathway as the disease circumvents lorlatinib, or may suggest a strategy for patients who present with dual ALK and RAS-MAPK pathway mutations. Here, ALK is linked to neuroblastoma.